There were 115,757 NH residents with dementia who self-reported pain in the last 30 days of life. 5 key findings →
Participants: 20,585 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
In a sample of 1218 new HCBS users (75% female, 77% Black; mean [SD] age, 70.5 [7.5] years), Medicaid HCBS initiation was associated with a decrease in probability of ED use (-2.70 percentage points; 95% CI, -4.18 to -1.22 percentage points) and a decrease in probability of inpatient discharge (-2.63 percentage points; 95% CI, -3.75 to -1.51 percentage points). 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
46/100
The findings indicate that stronger ESG practices significantly reduce corporate risk, enhance financial stability, and mitigate regulatory and market volatility exposure. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We examined state variations in assisted living (AL) regulatory policies for admission/retention, staffing/training, medication management, and dementia care. 3 key findings →
Participants: 46 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Loneliness, distinct from social isolation, is a subjective sense of social disconnection exacerbating a public health crisis among older adults. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The advancement of disease-modifying treatments (DMTs) for Alzheimer's disease (AD), along with the approval of three amyloid-targeting therapies in the US and several other countries, represents a significant development in the treatment landscape, offering new hope for addressing this once untreatable chronic progressive disease. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
To determine the risk for dementia in neurofibromatosis type 1 (NF1) using a Finnish nationwide cohort of individuals with NF1, and data from national registries. 2 key findings →
Participants: 1,349 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This Viewpoint discusses the potential benefits and harms of prior authorization in Medicare Advantage and the health policy implications and opportunities for improvement. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We estimated average per patient direct, indirect and total costs for the 6-month observation period. 2 key findings →
Participants: 145 Evidence: low
Full summary, score breakdown and related studies → Original source
The Centers for Medicare & Medicaid Services (CMS) established a class-based National Coverage Determination (NCD) for monoclonal antibodies directed against amyloid for Alzheimer's disease (AD) with patient access through Coverage with Evidence Development (CED) based on three questions. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Obesity is a significant health crisis affecting more than 123 million adults and children/adolescents in the US. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
3,001,987 Medicare beneficiaries were identified, of which 8.2% had a dementia diagnosis. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Of 2 684 704 Fee-for-Service patients with Alzheimer dementia, 769 141 met all inclusion criteria; among these, 281 042 (36.5%) had agitation. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This study evaluates whether patients enrolled in trials of aducanumab, EMERGE and ENGAGE, were representative of patients with dementia enrolled in Medicare by estimating the proportions of Medicare beneficiaries with Alzheimer disease (AD) or mild cognitive impairment (MCI) who would have been excluded from these trials. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Among 88 African Americans with cognitive impairment (mean = 10 years follow-up), Medicare claims identified dementia <2 years from cohort diagnosis in 55%; 27% were identified 2-9.9 years after cohort diagnosis, and in 18% there was either no claims diagnosis during the study period, or claims identified dementia 10+ years after cohort diagnosis. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
46/100
Out of pocket expenditures by families (N = 182) of relatives with dementia residing in the community were examined. 3 key findings →
Participants: 182 Evidence: low
Full summary, score breakdown and related studies → Original source
A total of 12,764,487 weighted older adults with ADRD were included, with 34.60% of them using anti-dementia drugs. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Donanemab provides clinical benefits but is unlikely to be cost-effective under current Australian thresholds. 3 key findings →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The results project substantial cost savings from implementing a blood test for AD pathology within the diagnostic pathway based on modeling results, which future research should confirm with actual data. 4 key findings →
Design: modelling Evidence: preliminary
Full summary, score breakdown and related studies → Original source Free full text
The Alzheimer's Disease Sequencing Project (ADSP) undertook whole exome sequencing in 5,740 late-onset Alzheimer disease (AD) cases and 5,096 cognitively normal controls primarily of European ancestry (EA), among whom 218 cases and 177 controls were Caribbean Hispanic (CH). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The cross-disciplinary expertise, required for GA, common in the days before medical specialization and enabled by the relative paucity of development in various fields compared with today, can be reborn with the advent of Electronic Health Records (EHR) systems that make the tools of medical geography accessible to a wide variety of health care researchers and clinical subspecialties. 4 key findings →
Participants: 127 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Approximately half of Medicare beneficiaries are enrolled in Medicare Advantage (MA), a private plan alternative to traditional Medicare (TM). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The study included 2,284,175 FFS Medicare beneficiaries with an ADRD diagnosis in 2017. 5 key findings →
Participants: 2,284,175 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
45/100
In 2020 Medicare reintroduced Alzheimer's disease and related dementias (ADRD) Hierarchical Condition Categories (HCCs) to risk-adjust Medicare Advantage and accountable care organization (ACO) payments. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Previous studies indicate that increased healthcare access through Medicaid expansion and alleviation of socioeconomic stressors via higher minimum wages improved health outcomes. 5 key findings →
Participants: 311 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
From across this tag
10 of the 705 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Patient-related risk factors for postoperative mortality and periprosthetic joint infection in medicare patients undergoing TKA
- Out-of-pocket costs attributable to dementia: A longitudinal analysis
- [P2–557]: HEALTH CARE USE AMONG NEWLY DIAGNOSED ALZHEIMER's (AD) PATIENTS IN A U.S. COMMERCIAL MEDICARE ADVANTAGE INSURANCE PLAN
- P3‐401: Impact of prescription drug coverage on use of anti‐dementia drugs
- Demographics, comorbidities, and comedications in newly diagnosed patients with Alzheimer's disease and related dementias: Findings from United States Medicare claims data
- Incidence and prevalence of dementia among US Medicare beneficiaries, 2015-21: population based study
- Healthcare costs among patients with dementia‐related psychosis: Comparing dementia with Lewy bodies with other dementias
- Economic Burden of Alzheimer Disease and Related Dementias by Race and Ethnicity, 2020 to 2060
- Telehealth among Medicare Advantage beneficiaries with and without Alzheimer's Disease and Related Dementias (ADRD), 2018–2024: from pandemic-era surge to post-pandemic decline
- Utilization and Lifetime Costs of Formal Care for Alzheimer's Disease Dementia in Sweden
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →